TIAA CREF Investment Management LLC acquired a new position in shares of Antares Pharma, Inc. (NASDAQ:ATRS) during the 2nd quarter, according to its most recent 13F filing with the SEC. The fund acquired 388,355 shares of the specialty pharmaceutical company’s stock, valued at approximately $1,251,000. TIAA CREF Investment Management LLC owned about 0.25% of Antares Pharma as of its most recent SEC filing.

A number of other hedge funds have also bought and sold shares of ATRS. Alliancebernstein L.P. purchased a new stake in Antares Pharma during the 2nd quarter worth approximately $119,000. Legal & General Group Plc purchased a new stake in Antares Pharma during the 2nd quarter worth approximately $120,000. Credit Suisse AG purchased a new stake in Antares Pharma during the 1st quarter worth approximately $146,000. National Planning Corp increased its holdings in Antares Pharma by 11.5% during the 2nd quarter. National Planning Corp now owns 58,233 shares of the specialty pharmaceutical company’s stock worth $186,000 after purchasing an additional 6,000 shares during the last quarter. Finally, KCG Holdings Inc. increased its holdings in Antares Pharma by 48.8% during the 1st quarter. KCG Holdings Inc. now owns 66,717 shares of the specialty pharmaceutical company’s stock worth $189,000 after purchasing an additional 21,881 shares during the last quarter. Institutional investors own 37.00% of the company’s stock.

A number of equities research analysts have recently weighed in on ATRS shares. Vetr upgraded Antares Pharma from a “buy” rating to a “strong-buy” rating and set a $3.42 price target for the company in a report on Monday, July 24th. HC Wainwright set a $5.00 price target on Antares Pharma and gave the company a “buy” rating in a report on Wednesday, August 9th. ValuEngine downgraded Antares Pharma from a “hold” rating to a “sell” rating in a report on Monday, October 16th. Finally, Piper Jaffray Companies set a $4.00 price target on Antares Pharma and gave the company a “buy” rating in a report on Wednesday, July 26th. One equities research analyst has rated the stock with a sell rating, three have assigned a buy rating and two have issued a strong buy rating to the stock. Antares Pharma has a consensus rating of “Buy” and an average target price of $3.84.

ILLEGAL ACTIVITY NOTICE: “388,355 Shares in Antares Pharma, Inc. (ATRS) Acquired by TIAA CREF Investment Management LLC” was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece of content on another domain, it was stolen and republished in violation of U.S. and international copyright and trademark law. The correct version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/11/08/388355-shares-in-antares-pharma-inc-atrs-acquired-by-tiaa-cref-investment-management-llc.html.

In related news, Director Thomas J. Garrity sold 30,000 shares of the business’s stock in a transaction that occurred on Tuesday, October 3rd. The stock was sold at an average price of $3.50, for a total transaction of $105,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Leonard S. Jacob sold 230,000 shares of the business’s stock in a transaction that occurred on Monday, October 9th. The shares were sold at an average price of $4.05, for a total value of $931,500.00. The disclosure for this sale can be found here. 11.60% of the stock is currently owned by insiders.

Shares of Antares Pharma, Inc. (ATRS) opened at $1.79 on Wednesday. Antares Pharma, Inc. has a twelve month low of $1.50 and a twelve month high of $4.09. The company has a current ratio of 3.47, a quick ratio of 3.04 and a debt-to-equity ratio of 0.61.

Antares Pharma (NASDAQ:ATRS) last issued its quarterly earnings results on Tuesday, November 7th. The specialty pharmaceutical company reported ($0.03) earnings per share for the quarter, meeting the Zacks’ consensus estimate of ($0.03). Antares Pharma had a negative return on equity of 41.37% and a negative net margin of 34.27%. The business had revenue of $15.10 million during the quarter, compared to the consensus estimate of $14.01 million. The firm’s revenue for the quarter was up 11.9% compared to the same quarter last year. equities research analysts anticipate that Antares Pharma, Inc. will post -0.11 EPS for the current fiscal year.

Antares Pharma Profile

Antares Pharma, Inc (Antares) is a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The Company develops and manufactures pressure-assisted injector devices, with and without needles, which allow patients to self-inject drugs.

Want to see what other hedge funds are holding ATRS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Antares Pharma, Inc. (NASDAQ:ATRS).

Institutional Ownership by Quarter for Antares Pharma (NASDAQ:ATRS)

Receive News & Stock Ratings for Antares Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma Inc. and related stocks with our FREE daily email newsletter.